Luis M. Ruilope

TL;DR: Investigation of the safety and tolerability of the combination of valsartan and benazepril indicates that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotsin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure.

TL;DR: The prevalence of masked suboptimal BP control in patients with treated and well-controlled clinic BP is high and ABPM should become more routine to confirm BP control, especially in higher risk groups and/or those with borderline control of clinic BP.

TL;DR: The HFA‐ESC convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework, and this report summarizes the group's recommendations for achieving common views on heart failureEndpoint selection.

TL;DR: In clinical practice, renal denervation resulted in significant reductions in office and 24-hour BPs with a favorable safety profile, and greater BP-lowering effects occurred in patients with higher baseline pressures.

TL;DR: In this paper, the effectiveness of BP control outside the clinic by using ambulatory BP monitoring (ABPM) among a large number of hypertensive subjects treated in primary care centers across Spain was studied.